Transgene Biotek share price
BSE: 526139Healthcare ServicesSmall Cap
Share price at the BSE close on 23 Oct 2026. Previous close ₹2.37.
- Under BSE's graded surveillance, stage 0, on the list for 22 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹19 Cr4,238th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 29 May 2026
- 2.3
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 7 Aug 2026
- −17.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 7 Aug 2026
- −2.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 2.05
- Volume, BSEVolume. Shares traded on the last trading day.
- 26,565
Results
Standalone, as consolidated accounts are on record for only 6 of the last ten years; ₹ crore, the charts by years to March, the table by quarter. No standalone results on record for the year to Mar 2023.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 7 Aug
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹0.06 Crup 10.09%
- Net profitNet profit. Under it, net profit in the quarter before. A change in per cent is not worked out where either period is a loss or nothing.
- −₹0.39 CrQuarter to Mar 2026: −₹0.46 Cr
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- −648.3%
Revenue by year
Net profit by year, a loss in red
- Net profit
- Loss
The years either side of a change of basis do not compare. From the year to Mar 2019, the company's revenue for that year, ₹0.07 Cr, differs from its quarters added, ₹2.07 Cr.
| ₹ crore | Sep 2024Filed 13 Nov | Dec 2024Filed 24 Jan | Mar 2025Filed 10 Jun | Jun 2025Filed 7 Aug | Sep 2025Filed 14 Nov | Dec 2025Filed 24 Feb | Mar 2026Filed 29 May | Jun 2026Filed 7 Aug |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.06 | 0.08 | 0.08 | 0.05 | 0.05 | 0.05 | 0.05 | 0.06 |
| Net profit | −0.07 | −0.09 | −0.71 | −0.43 | −0.39 | −0.37 | −0.46 | −0.39 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | −125.5% | −116.3% | −932.2% | −876.2% | −735.6% | −685.7% | −838.5% | −648.3% |
Business segments
In the year to Mar 2026 the company reports one business segment, PHARMACY, which carries all its revenue.
Valuation
Today, against the company's own history. Not shown, P/E: loss, last twelve months. Not shown, EV/EBITDA: operating loss, last twelve months. Dividend yield is not shown: no dividend in the years on record.PE ratio and valuation history
At or below today's level on 11% of 717 trading days over the last 3 years.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −40.9% | – | – | 0.0% |
| 3 years | −7.4% | – | – | 0.0% |
| 5 years | −15.4% | – | – | 0.0% |
Peers and competitors
Healthcare Service Provider, 36 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Transgene Biotek in market cap. 1 company in the table last traded before then: its row is priced on its last trade.
Transgene Biotek is not on the chart: it has no P/E today
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Deccan Health CareDECCAN | 29 | 11.3 | 0.3 | 5.9 | −0.4% | +145.9% | 2.3% | 3.3% | 0.00% |
 Chennai Meenakshi Multispeciality HospitalCMMHOSP | 27 | – | – | 59.1 | +6.5% | – | – | −6.7% | 0.00% |
 Sharma East India Hospitals and ResSHARMEH | 26 | 21.9 | 1.9 | 9.2 | +14.1% | −9.9% | 9.0% | 9.1% | 0.00% |
 Tejnaksh HealthcareTEJNAKSH | 24 | 19.2 | 0.9 | 7.6 | −13.0% | −37.0% | 4.7% | 5.2% | 0.00% |
 Nidan Laboratories and HealthcareNIDAN | 17 | 11.4 | 0.2 | – | +4.1% | −23.8% | 2.2% | – | 0.00% |
 Family Care HospitalsFAMILYCARE | 11 | – | 1.1 | – | −93.9% | – | −73.4% | −27.5% | 0.00% |
 Dolphin Medical ServicesDOLPHMED | 10 | – | 1.0 | – | – | – | – | – | 0.00% |
 Dhanvantri Jeevan RekhaZDHJERK | 10 | – | 0.9 | 5.7 | +49.9% | – | – | 1.9% | 0.00% |
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
5 Oct · Board meeting
Meeting on 10 Oct 20263 Oct · Compliance-57 (5) : intimation after the end of quarter
3 Oct · Compliance-57 (4) : Prior intimation to the beginning of the quarter
3 Oct · Compliance Certificate Pursuant To Regulation 7(3) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Transgene Biotek share price by year
Each calendar year to 2025.Transgene Biotek share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 3.15 | −53.9% | 6.15 | 2.72 |
| 2024 | 6.83 | −30.8% | 11.98 | 5.84 |
| 2023 | 9.87 | +234.6% | 11.10 | 2.31 |
| 2022 | 2.95 | −33.7% | 4.23 | 2.75 |
| 2021 | 4.45 | −8.8% | 5.82 | 3.18 |
| 2020 | 4.88 | +117.9% | 6.72 | 2.29 |
| 2019 | 2.24 | −32.5% | 5.97 | 2.11 |
| 2018 | 3.32 | +45.6% | 4.10 | 1.90 |
| 2017 | 2.28 | −1.3% | 3.35 | 1.74 |
| 2016 | 2.31 | −10.5% | 2.89 | 1.61 |
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on BSE.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 23 Oct 2026 | 2.46 | 2.65 | 2.37 | 2.57 | 2.45 | 26,565 |
| 22 Oct 2026 | 2.45 | 2.68 | 2.30 | 2.37 | 2.39 | 11,220 |
| 21 Oct 2026 | 2.55 | 2.55 | 2.39 | 2.44 | 2.42 | 4,455 |
| 19 Oct 2026 | 2.60 | 2.60 | 2.35 | 2.49 | 2.45 | 10,850 |
| 16 Oct 2026 | 2.55 | 2.69 | 2.54 | 2.55 | 2.58 | 5,754 |
| 15 Oct 2026 | 2.64 | 2.65 | 2.48 | 2.52 | 2.55 | 9,946 |
| 14 Oct 2026 | 2.53 | 2.70 | 2.53 | 2.64 | 2.63 | 4,956 |
| 13 Oct 2026 | 2.71 | 2.78 | 2.60 | 2.65 | 2.69 | 4,595 |
| 12 Oct 2026 | 2.94 | 2.94 | 2.45 | 2.66 | 2.67 | 45,491 |
| 9 Oct 2026 | 2.35 | 2.52 | 2.31 | 2.47 | 2.46 | 12,481 |
Company details
- Legal name
- Transgene Biotek Ltd.
- BSE code
- 526139
- ISIN
- INE773D01018
- Industry
- Healthcare Services
- Listed
- Dec 1993
- Face value
- ₹10
- CIN
- L85195TG1990PLC011065
- Corporate identity number, the registrar of companies' code for it